Tyrosine kinase inhibitor (TKI) therapy targeting the BCR-ABL1 kinase is effective against
chronic myeloid leukaemia (CML), but is not curative for most patients. Minimal residual …

Genomic testing enables clinical management to be tailored to individual cancer patients
based on the molecular alterations present within cancer cells. Genomic sequencing results …

In contrast to adult medicine, specific scoring systems predicting the treatment response for
an individual pediatric patient (pt) with chronic myeloid leukemia (CML) have not yet been …

We report results of studies relating to the fabrication of a surface plasmon resonance (SPR)-
based nucleic acid sensor for quantification of DNA sequence specific to chronic …

Chronic myeloid leukemia (CML) is a hematological disease accounting for about 15-20% of
all adult leukemias. The clinical and biologic advances achieved in such a malignancy …

Chronic myeloid leukemia is a stem cell-initiated but progenitor-driven disease induced by
the BCR–ABL oncogene. Tyrosine kinase inhibitors (TKIs) were introduced in the late 1990s …

Treatment of chronic myeloid leukemia (CML) with target therapy approved 5 different
tyrosine kinase inhibitors (TKIs; imatinib, nilotinib, dasatinib, bosutinib and ponatinib) …

Hematologic malignancies represent a diverse group of neoplastic conditions that arise from
hematopoietic cells. Myeloid neoplasms represent clonal expansions of myeloid progenitors …

Advances in defining the mutational landscape of myeloproliferative neoplasms (MPNs)
over the past decade have revolutionized the molecular diagnosis of these entities …

Chronic myelogenous leukemia (CML) is a myeloproliferative neoplasm that has become a
paradigm of targeted molecular therapy, as well as molecular diagnosis and disease …